Recent clinical studies in patients with type 2 diabetes with or without heart failure showed that the SGLT2 inhibitors dapagliflozin, empagliflozin, canagliflozin, and ipragliflozin significantly reduced the estimated extracellular volume and estimated plasma volume for up to 24 months (33, 44–46). Here, SLC5A2 is linked to heart failure.